Joachim Blanz

1.3k citations

31 papers · 967 indexed · h-index 14

Co-authors: Gerhard Ehninger Klaus‐Peter Zeller Barbara Proksch Mark Knapp Pascal Furet Reiner Aichholz Ulrich S. Schuler Patricia Imbach‐Weese
Topics: Cancer Treatment and Pharmacology (6 papers)Synthesis and biological activity (4 papers)Quinazolinone synthesis and applications (4 papers)
Cited by: Genetics Toxicology Hematology
Journals: Blood Journal of Medicinal Chemistry Pure and Applied Chemistry
Partner nations: Germany Switzerland United States

In The Last Decade

Joachim Blanz

30 papers receiving 946 citations

Peers

Countries citing papers authored by Joachim Blanz

Since Specialization

Citations

This map shows the geographic impact of Joachim Blanz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joachim Blanz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joachim Blanz more than expected).

Fields of papers citing papers by Joachim Blanz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joachim Blanz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joachim Blanz. The network helps show where Joachim Blanz may publish in the future.

Co-authorship network of co-authors of Joachim Blanz

This figure shows the co-authorship network connecting the top 25 collaborators of Joachim Blanz. A scholar is included among the top collaborators of Joachim Blanz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joachim Blanz. Joachim Blanz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment 2021 ·Xenobiotica ·(unknown),(unknown),Jiang-Wei Zhang,Michael Kiffe,Markus Walles,Yi Jin,Joachim Blanz,(unknown),(unknown),Chunye Zhang,Lijun Zhang,Ying Huang,Counde O-Yang	7
2	Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors 2017 ·ACS Medicinal Chemistry Letters ·Klemens Hoegenauer,Nicolas Soldermann,Frédéric J. Zécri,(unknown),(unknown),Romain M. Wolf,Nigel G. Cooke,Alexander B. Smith,Gregory J. Hollingworth,Joachim Blanz,Sascha Gutmann,Gabriele Rummel,Amanda Littlewood‐Evans,Christoph Burkhart	84
3	Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors 2016 ·Bioorganic & Medicinal Chemistry Letters ·Robin A. Fairhurst,Giorgio Caravatti,Vito Guagnano,Reiner Aichholz,Joachim Blanz,Francesca Blasco,(unknown),Christine Fritsch,Sauveur-Michel Maira,Christian Schnell,(unknown)	1
4	Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors 2016 ·ACS Medicinal Chemistry Letters ·Klemens Hoegenauer,Nicolas Soldermann,Frédéric Stauffer,Pascal Furet,(unknown),Alexander B. Smith,(unknown),Gregory J. Hollingworth,Ian Lewis,Sascha Gutmann,Gabriele Rummel,Mark Knapp,Romain M. Wolf,Joachim Blanz,Roland Feifel,Christoph Burkhart,Frédéric J. Zécri	49
5	Micropreparative isolation and NMR structure elucidation of metabolites of the drug candidate 1-isopropyl-4-(4-isopropylphenyl)-6-(prop-2-yn-1-yloxy) quinazolin-2(1H)-one from rat bile and urine 2015 ·Journal of Chromatography B ·Joachim Blanz,(unknown),David Pearson,(unknown),M. RITZAU,(unknown),(unknown),(unknown),Sandrine Desrayaud,Elisabeth Braun,Reiner Aichholz	6
6	Orally bioavailable Syk inhibitors with activity in a rat PK/PD model 2015 ·Bioorganic & Medicinal Chemistry Letters ·Gebhard Thoma,Siem J. Veenstra,(unknown),Joachim Blanz,Eric Vangrevelinghe,(unknown),Christian C. Lee,Hans‐Günter Zerwes	6
7	Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors 2015 ·Bioorganic & Medicinal Chemistry Letters ·Robin A. Fairhurst,Marc Gerspacher,Patricia Imbach‐Weese,Robert Mah,Giorgio Caravatti,Pascal Furet,Christine Fritsch,Christian Schnell,Joachim Blanz,Francesca Blasco,Sandrine Desrayaud,Daniel Guthy,Mark Knapp,(unknown),(unknown),(unknown),(unknown)	15
8	Discovery and Profiling of a Selective and Efficacious Syk Inhibitor 2015 ·Journal of Medicinal Chemistry ·Gebhard Thoma,Alexander B. Smith,Maurice J. van Eis,Eric Vangrevelinghe,Joachim Blanz,Reiner Aichholz,Amanda Littlewood‐Evans,Christian C. Lee,Hong Liu,Hans‐Günter Zerwes	19
9	Syk inhibitors with high potency in presence of blood 2014 ·Bioorganic & Medicinal Chemistry Letters ·Gebhard Thoma,Joachim Blanz,Peter Bühlmayer,Peter Drückes,Matthias Kittelmann,Alexander B. Smith,(unknown),Eric Vangrevelinghe,Hans‐Günter Zerwes,Jianwei Che,(unknown),Yunho Jin,Christian C. Lee,Pierre‐Yves Michellys,Tetsuo Uno,Hong Liu	17
10	Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation 2013 ·Bioorganic & Medicinal Chemistry Letters ·Pascal Furet,Vito Guagnano,Robin A. Fairhurst,Patricia Imbach‐Weese,Ian C. Bruce,Mark Knapp,Christine Fritsch,Francesca Blasco,Joachim Blanz,Reiner Aichholz,Jacques Hamon,Doriano Fabbro,Giorgio Caravatti	350
11	Exploring subtype selectivity and metabolic stability of a novel series of ligands for the benzodiazepine binding site of the GABAA receptor 2010 ·Bioorganic & Medicinal Chemistry Letters ·Samuel Hintermann,Konstanze Hurth,Joachim Nozulak,Marina Tintelnot‐Blomley,Reiner Aichholz,Joachim Blanz,Klemens Kaupmann,Johannes Mosbacher	5
12	Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile 2010 ·ACS Medicinal Chemistry Letters ·David A. Carcache,Ivo Vranesic,Joachim Blanz,Sandrine Desrayaud,Markus Fendt,Ralf Glatthar	7
13	Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? 1994 ·PubMed ·Ulrich S. Schuler,Stephanie A. Schroer,(unknown),Joachim Blanz,(unknown),(unknown),Barbara Proksch,(unknown),Gerhard Ehninger	77
14	Synthesis and structural elucidation of biliary excreted thioether derivatives of mitoxantrone 1994 ·Xenobiotica ·(unknown),Joachim Blanz,Stefan M.V. Freund,Gerhard Ehninger,Klaus‐Peter Zeller	7
15	Detection and separation of the anthrapyrazole CI-941 and its metabolites in serum and urine by high-performance liquid chromatography 1994 ·Journal of Chromatography B Biomedical Sciences and Applications ·Barbara Proksch,Joachim Blanz,Klaus‐Peter Zeller,G. Ehninger	4
16	Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. 1993 ·PubMed ·(unknown),Joachim Blanz,Gerhard Ehninger,Rolf Gebhardt,Klaus‐Peter Zeller	57
17	Pharmacokinetics and Metabolism of Mitoxantrone 1990 ·Clinical Pharmacokinetics ·Gerhard Ehninger,Ulrich S. Schuler,Barbara Proksch,Klaus‐Peter Zeller,Joachim Blanz	96
18	Quantitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis 1990 ·Journal of Chromatography B Biomedical Sciences and Applications ·Joachim Blanz,(unknown),Barbara Proksch,Gerhard Ehninger,Klaus‐Peter Zeller	28
19	The isolation and identification of indigo and indirubin from urine of a patient with leukemia. 1989 ·PubMed ·Joachim Blanz,Gerhard Ehninger,(unknown)	8
20	¹³C‐Markierung der Seitenketten von Mitoxantrone 1989 ·Journal of Labelled Compounds and Radiopharmaceuticals ·Joachim Blanz,Klaus‐Peter Zeller	3

About Joachim Blanz

Joachim Blanz is a scholar working on Pharmaceutical Science, Toxicology and Organic Chemistry, having authored 31 papers that have together received 967 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), Synthesis and biological activity (4 papers) and Quinazolinone synthesis and applications (4 papers). The work is most often cited by research in Genetics (152 citations), Toxicology (40 citations) and Hematology (123 citations). Joachim Blanz has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Gerhard Ehninger, Klaus‐Peter Zeller, Barbara Proksch, Mark Knapp, Pascal Furet, Reiner Aichholz, Ulrich S. Schuler, Patricia Imbach‐Weese, Christine Fritsch and Giorgio Caravatti. Their work appears in journals such as Blood, Journal of Medicinal Chemistry and Pure and Applied Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact